Malt-1 modulators
AssigneeExscientia AI Limited
InventorsPeter Ray, David Evans, Anthony Bradley, Chris Radoux, Simon Richards, Catarina Santos, Jérémy Besnard, Andrew John Cooke, Sylvie Félicité Gomez, Lorène Nathalie Sabine Cazaux-Lerou, Marta Pinto, Sabrina Pucci, Claire Christiane Ginette Blanger
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of MALT-1. Such compounds are represented by Formula (I) and Formula (II), wherein the variables are defined herein.
Claims30
A compound of formula (I):
- wherein:
- Q is N or CRa, where Ra is selected from hydrogen, OH, alkyl, alkoxy;
- X, Y and Z are each selected independently from N or CRb, where Rb is selected from hydrogen, alkoxy, alkyl, halo alkyl, halogen;
- V is selected from the group consisting of:
- CO, SO and SO2;
- R1 is selected from the group consisting of:
- alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxy, cycloalkyl, a 4-7 membered saturated or unsaturated heterocyclic ring having heteroatoms selected from N, S and O optionally substituted with hydroxyl, nitrile, oxo, amino, aminoalkyl and/or dioxo, sulfonyl, sulfoxide, sulfoximine, alkyl sulfonyl, alkyl sulfoxide, cycloalkyl sulfonyl, cycloalkyl sulfoxide, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl;
- or one of the following structures:
- any one of the following structures:
- where each of the aforementioned hydrocarbon groups may be further substituted by one or more residues independently selected from halogen, hydroxyl, nitrile or C1-4-alkoxy groups;
- R2 is selected from the group consisting of:
- hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl;
- or
- R1 and R2 together form a 4-7 membered ring;
- particularly a 5-6 membered heterocyclic ring having a further heteroatom selected from N, or O, which is optionally substituted with oxo, amino, aminoalkyl, sulfoxide, sulfoxide imine, sulfonyl, alkyl sulfoxide, sulfoximine, alkyl sulfonyl, cycloalkyl sulfoxide, cycloalkyl sulfonyl, sulfamoyl, alkyl sulfamoyl, cycloalkyl sulfamoyl;
- R3 is selected from the group consisting of:
- hydrogen, C1-3 alkyl, C1-3 alkoxyl, or C1-3 haloalkyl;
- R4 and R5 are each independently selected from the group consisting of:
- hydrogen, C1-3 alkyl, pyridinyl, phenyl, pyrazidinyl or pyrimidinyl, optionally wherein the pyridinyl, phenyl, pyrazidinyl or pyrimidinyl is fused with a pyrrolyl, phenyl, pyrimidinyl, pyrazidinyl, imidazolyl, triazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, quinazolinyl, which may be optionally substituted with C1-3 alkyl, C1-3 alkoxy, cyano, amine, difluoromethyl or halogen;
- or
- R4 and R5 together with the Q to which they attach form a non-aromatic heterocyclic 4-8 membered ring containing at least one heteroatom, particularly nitrogen, and optionally an additional heteroatom such as nitrogen or oxygen;
- and wherein the ring is fused with phenyl, pyridinyl, pyrazidinyl, pyrimidinyl which may be optionally substituted with halogen, nitrile, methyl, methoxy, difluoromethyl, aminyl, or trifluoromethyl, pyrazidinyl or pyrimidinyl, wherein the phenyl, pyridinyl, pyrazidinyl or pyrimidinyl is optionally fused with a further heterocyclic 5- or 6-membered ring, which is optionally substituted with 1 to 3 groups selected from the group consisting of:
- C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, pyrrolyl, imidazolyl, triazolyl, nitro, cyano, hydroxyl or halogen;
- or
- R4 and R5 together with the Q to which they attach form one of the following structures:
- M, R and A are selected independently from the group consisting of:
- N, S or C, preferably M and R are selected independently from the group consisting of:
- N, S or C and A is C;
- U is selected from the group consisting of:
- N, or CRc, wherein Rc is selected from hydrogen, halogen or alkyl;
- R6 and R6′ are independently selected from the group consisting of:
- hydrogen, halogen C1-3 alkyl, C1-3 alkoxyl, C1-3 alkyl alkoxy, hydroxyl, alkyl hydroxyl, amino alkyl, C1-3 alkyl amino alkyl, tertiary aminyl, cyclic aminyl, spirocyclic aminyl, C1-2 alkyl-4-6 saturated heterocyclic aminyl, C0-2 alkyl oxetane, C0-2 alkyl oxolane, C0-2 alkyl azetidinyl or C0-2 alkyl pyrrolidinyl, C1-3 carboxyl, C1-3 haloalkyl, methylacetyl (OAc) or ethanoate;
- alternatively, R6′ and R6 together form a C3-5 membered saturated ring or C4-5 membered saturated heterocycle ring containing oxygen;
- R7 is selected from the group consisting of:
- C1-3 alkyl, C1-3 alkoxyl, C1-3 haloalkyl, nitro, cyano, SMe, SOMe, SO2Me, pyrrolyl, imidazolyl, triazolyl, or halogen;
- and
- R8 and R9 are each independently selected from the group consisting of:
- hydrogen, C1-3 alkyl, C1-3 alkoxyl, hydroxyl, C1-3 hydroxyalkyl or halogen.
-4. (canceled)
-9. (canceled)
-16. (canceled)
-19. (canceled)
(canceled)
A compound or a pharmaceutical composition comprising a compound, wherein the compound is selected from:
- (i) the group of compounds shown in Table 1;
- (ii) the group of compounds of Table 1 having an IC50 against Malt-1≤250 nM;
- (iii) the group of compounds of Table 1 having an IC50 against Malt-1≤200 nM;
- (iv) the group of compounds of Table 1 having an IC50 against Malt-1≤150 nM;
- (v) the group of compounds of Table 1 having an IC50 against Malt-1≤100 nM;
- (vi) the group of compounds of Table 1 having an IC50 against Malt-1≤50 nM;
- or
- (vii) the group of compounds of Table 1 having an IC50 against Malt-1≤25 nM.
A compound or a pharmaceutical composition comprising a compound, wherein the compound is selected from any one of the compounds of Examples 1 to 295, or a pharmaceutically acceptable salt, solvate, prodrug, or pharmaceutically active metabolite thereof, or combinations thereof;
- and wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers.
-56. (canceled)
-59. (canceled)
-63. (canceled)
Dependencies are inferred from the claim text.